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Benzofuran is one of the most important classes of fused ring
heterocyclic compounds. The benzofuran derivatives are natu-
rally occurring and possess many biological applications [1–3].
Angelicin, Psoralen and bergapten are the examples of natu-
rally occurring benzofuran derivatives with biological applica-
tions [4–6] (Fig. 1). The isolation of benzofuran derivatives
from natural sources is laborious and time consuming. So
the synthetic chemists are interested in synthesizing the benzo-
furan derivatives. Numerous synthesized benzofuran deriva-
tives were found to be biologically active [7–9]. Now a days
many synthetic benzofurans are used as good inhibitor
[10,11], antimicrobial [12–14], anti-inﬂammatory [15,16],antiviral [17], antioxidant [18,19], anti-tumour [20], antiprolif-
erative [21,22] and anti-alzheimer [23] (Fig. 2).
In skeleton modiﬁcations of the benzofurans are possible in
six different positions. For example, Marriott et al. proved
that benzofuran-2-carboxamide derivatives act as sigma recep-
tors [24] and Wu et al. synthesized modiﬁed benzofuran as
SIRT1 inhibitor [10]. Similarly Kirilmis et al. reported the
antimicrobial activity of benzofuran-2-ethanone derivatives
[14] and Xie et al. reported the anti-inﬂammatory activity of
benzofuran-2-carboxalamide derivatives [25].
The role of amino acid is very important in biological sys-
tems [26,27]. Some of the well-known derivatives of amino
acids such as L-Dopa and eﬂornithine revealed pharmaceutical
applications [28–30]. The peptide based benzofuran derivatives
have shown potent biological activities [31–33]. On the basis of
above facts, we focused to synthesize new benzofuran-2-
carboxamide derivatives (5a–o) in our laboratory. The modiﬁ-
cations are executed at the C3 carbon of the benzofuran with
glycinamide and b-alanamide unit. The synthesized
compounds were thoroughly characterized, conﬁrmed and
their in vitro biological activities such as antimicrobial, anti-
inﬂammatory and DPPH scavenging activities were evaluated.hemical
Angelicin psoralen
bergapten nodakenetine
Figure 1 Naturally occurred benzofuran derivatives.
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Figure 2 Examples for benzofuran based drugs.
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2.1. General consideration
Melting points were recorded on sigma melting apparatus
SL111140. IR spectrum was recorded in JASCO FT-IR410
spectrometer using KBr pellet making method. 1H NMR
and 13C NMR spectra were recorded on Bruker 300 MHz
instrument in CDCl3 with TMS as an internal standard for
proton and carbon spectra. Chemical shift values are men-
tioned in d (ppm) and coupling constants are given in Hz.
Mass spectra were recorded on Absciex 3000 LC–MS–MS.
The progress of all reactions was monitored by TLC on
2 · 5 cm pre-coated silica gel 60 F254 plates of thickness of
0.25 mm (Merck). The chromatograms were visualized under
UV 254–366 nm, iodine and potassium permanganate solu-
tion. The elemental analyses were recorded in vario EL III
CHNS elemental analyser. The single crystal X-ray data were
recorded in Bruker Kappa APEXII single crystal X-ray
diffractometer (Enraf Nonlus CAD4-MV31), SAIF, IIT
Madras.
2.2. Synthesis of 2-(cyanomethoxy)benzonitrile (2)
To a stirred solution of 2-hydroxy benzonitrile 1 (0.083 mol) in
DMF (50 mL), potassium carbonate (0.166 mol) and 2-chloro
acetonitrile (0.101 mol) were added in room temperature. The
reaction mixture was reﬂuxed to 80 C for 3 h. Then the reac-
tion mixture was poured into ice cold water and ﬁltered. The
solid obtained was washed with minimum amount of hexane,
and then dried to get compound 2.
Brown solid, Yield 90%, mp: 56–58 C. IR (KBr) cm1:
3170, 2230, 1181, 733. 1H NMR (CDCl3, 300 MHz): d 7.62–
7.68 (m, 2H), 7.11–7.23 (m, 2H), 4.94 (s, 2H). 13C NMR
(CDCl3, 75 MHz): d 157.66, 134.72, 134.44, 123.36, 115.47,
114.20, 112.55, 102.96, 53.90. ESI-MS (M1) calculated.
m/z 158.05. found 156.9. Anal. Calcd for: C9H6N2O: C,
68.35; H, 3.82; N, 17.71% found: C, 68.39; H, 3.81; N,
17.69%.Please cite this article in press as: A. Lavanya et al., Synthesis and biological evalu
Society (2015), http://dx.doi.org/10.1016/j.jscs.2015.06.0082.3. Synthesis of 3-amino-1-benzofuran-2-carboxamide (3)
To a solution of (2-cyanomethoxy)benzonitrile 2 (0.0632 mol)
in ethanol (100 mL), KOH (0.178 mol) was added. The reac-
tion mixture was reﬂuxed to 75 C for 3 h, and then the reac-
tion mixture was poured into the ice cold water and ﬁltered.
Solid obtained was dried to afford compound 3.
White solid, Yield 65%, mp: 144–146 C. IR (KBr) cm1:
3426, 3162, 1646, 1567, 1171, 734. 1H NMR (CDCl3,
300 MHz): d 7.56 (d, J= 9.0 Hz, 1H), 7.35–7.46 (m, 2H),
7.26 (d, J= 9.0 Hz, 1H), 5.97 (s, 2H), 5.06 (s, 2H). 13C
NMR (CDCl3, 75 MHz): d 162.85, 151.78, 135.63, 126.78,
125.76, 121.73, 120.96, 119.79, 110.69. ESI-MS (M++1) cal-
culated. m/z 176.7. found 177.2. Anal. Calcd for: C9H8N2O2:
C, 61.36; H, 4.58; N, 15.90% found: C, 61.37; H, 4.57; N,
15.90%.
2.4. General procedure for the synthesis of 3-[(chloroalkyl)amino]
benzofuran-2-carboxamide (4a, 4b)
To a stirred solution of 3-amino-1-benzofuran-2-carboxamide
3 (0.0227 mol) in dichloromethane (100 mL), triethylamine
was added (0.0646 mol) at 0–5 C. To this mixture acid
chloride (0.0267 mol) was added drop wise over 5 min. After
completion of addition, the reaction was stirred at ambient
temperature for 4 h. Then the reaction mixture was diluted
with dichloromethane (100 mL), washed with water
(2 · 50 mL) and brine solution (50 mL). The organic layer
was dried over anhydrous sodium sulphate, ﬁltered and evap-
orated to afford the desired product (4a and 4b).
2.4.1. Compound 4a
White solid, Yield 70%, mp: 145–147 C. IR (KBr) cm1:
3436, 3145, 1650, 1594, 1177, 746, 670. 1H NMR (CDCl3,
300 MHz): d 11.26 (s, 1H), 8.58 (d, J= 8.7 Hz, 1H), 7.40–
7.48 (m, 2H), 7.31 (d, J= 6.6 Hz, 1H), 6.42 (s, 1H), 5.67 (s,
1H), 3.93 (s, 2H). 13C NMR (CDCl3, 75 MHz): d 171.51,
162.80, 153.67, 132.11, 128.39, 128.28, 127.46, 123.22, 122.32,
111.57, 47.23. ESI-MS (M++1) calculated. m/z 252.0.
Found 253.1. Anal. Calcd for: C11H9ClN2O3: C, 52.29; H,
3.59; N, 11.09% found: C, 53.01; H, 3.60; N, 11.10%.
2.4.2. Compound 4b
White solid, Yield 71%, mp: 220–222 C. IR (KBr) cm1:
3438, 3148, 1654, 1596, 1178, 744, 673. 1H NMR (CDCl3,
300 MHz): 11.25 (s, 1H), 8.57 (d, J= 8.7 Hz, 1H), 7.39–7.48
(m, 2H), 7.32 (d, J= 6.6 Hz, 1H), 6.43 (s, 1H), 5.68 (s, 1H),
3.89 (t, J= 6.0 Hz, 2H), 2.99 (t, J= 6.0 Hz, 2H). 13C NMR
(DMSO-D6, 75 MHz): d 169.94, 162.03, 152.69, 132.80,
125.82, 125.53, 124.28, 122.47, 122.36, 111.18, 42.31, 34.04.
ESI-MS (M++1) calculated. m/z 266.05. found 267.06.
Anal. Calcd for: C12H11ClN2O3: C, 54.05; H, 4.16; N,
10.50% found: C, 54.01; H, 4.17; N, 10.51%.
2.5. General procedure for the synthesis of 3-(2-(substituteda-
mino)acetamido)benzofuran-2-carboxamide derivatives (5a–o)
To a solution of 3-[(chloroacetyl)amino]-1-benzofuran-2-car
boxamide 4 (0.0012 mol) in dichloromethane (10 mL), triethy-
lamine (0.0024 mol) and corresponding amines (0.0014 mol)ation of new benzofuran carboxamide derivatives, Journal of Saudi Chemical
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mixture was diluted with dichloromethane (50 mL), washed
with water (2 · 25 mL) and brine (25 mL). The organic layer
was dried over anhydrous sodium sulphate, ﬁltered and evap-
orated to get the expected compound.
2.5.1. Compound 5a
White solid. Yield 75%. mp: 125–127 C. IR (KBr) cm1:
3438, 3170, 1656, 1597, 1181, 1153, 746. 1H NMR (CDCl3,
300 MHz): d 11.21 (s, 1H), 8.53 (d, J= 8.4 Hz, 1H), 7.41–
7.48 (m, 2H), 7.26 – 7.31 (m, 3H), 7.20 (d, J= 8.7 Hz, 1H),
6.46 (s, 1H), 5.67 (s, 1H), 3.86 (s, 2H), 3.80 (s, 3H), 3.81 (s,
3H), 3.42 (s, 2H). 13C NMR (CDCl3, 75 MHz): d 174.97,
168.45, 167.13, 157.62, 141.27, 137.46, 133.63, 133.53, 132.97,
132.27, 131.38, 131.34, 127.31, 116.22, 111.43, 104.58, 58.95,
56.33, 54.46, 52.54. ESI-MS (M++1) calculated. m/z 383.4.
found 384.3. Anal. Calcd for: C20H21N3O5: C, 62.65; H,
5.52; N, 10.96% found: C, 62.68; H, 5.55; N, 10.91%.
2.5.2. Compound 5b
White solid. Yield 74%. mp: 147–149 C. IR (KBr) cm1: 3440,
3172, 1655, 1587, 1171, 740. 1H NMR (CDCl3, 300 MHz): d
11.27 (s, 1H), 8.58 (d, J= 8.7 Hz, 1H), 7.40–7.48 (m, 2H),
7.31 (d, J= 6.6 Hz, 1H), 6.42 (s, 1H), 5.67 (s, 1H), 3.49 (s,
2H), 2.68–2.72 (m, 2H), 1.92–1.95 (m, 2H), 1.47–1.66 (m,
10H). 13C NMR (CDCl3, 75 MHz): d 171.51, 162.80, 153.67,
132.11, 128.39, 128.28, 127.46, 123.22, 122.32, 111.57, 53.55,
51.13, 35.09, 28.38, 24.27. ESI-MS (M++1) calculated. m/z
329.2. found 330.2. Anal. Calcd for: C18H23N3O3: C, 65.63;
H, 7.04; N, 12.76% found: C, 65.65; H, 7.06; N, 12.75%.
2.5.3. Compound 5c
Yellow solid. Yield 71%. mp: 165–167 C. IR (KBr) cm1:
3292, 3173, 1681, 1615, 1190, 745. 1H NMR (CDCl3,
300 MHz): d 11.18 (s, 1H), 8.52 (d, J= 8.1 Hz, 1H), 7.43–
7.46 (m, 2H), 7.33 (d, J= 8.1 Hz, 2H), 7.28–7.29 (m, 1H),
7.15 (d, J= 7.5 Hz, 2H), 6.40 (s, 1H), 5.75 (s, 1H), 3.89 (s,
2H), 3.52 (s, 2H), 2.32 (s, 3H). 13C NMR (CDCl3, 75 MHz):
d 174.97, 168.45, 167.13, 157.62, 141.27, 137.46, 133.63,
133.53, 132.97, 132.27, 131.38, 131.34, 127.31, 116.22, 58.05,
56.93, 25.64. ESI-MS (M++1) calculated. m/z 337.1 found
338.3. Anal. Calcd for: C19H19N3O3: C, 67.64; H, 5.68; N,
12.46% found: C, 67.65; H, 5.69; N, 12.44%.
2.5.4. Compound 5d
White solid. Yield 78%. mp: 131–133 C. IR (KBr) cm1: 3292,
3127, 1664, 1600, 1217 1195, 748. 1H NMR (CDCl3, 300 MHz):
d 11.18 (s, 1H), 8.53 (d, J= 8.1 Hz, 1H), 7.43–7.47 (m, 4H),
7.31 (d, J= 6.3 Hz, 1H), 7.01–7.07 (m, 2H), 6.41 (s, 1H),
5.86 (s, 1H), 3.89 (s, 2H), 3.54 (s, 2H). 13C NMR (CDCl3,
75 MHz): d 170.26, 163.04, 153.64, 148.20, 135.10, 132.01,
130.17, 130.06, 128.43, 127.32, 123.34, 115.60, 115.32, 111.67,
53.47, 52.59. ESI-MS (M++1) calculated. m/z 341.1. found
342.2. Anal. Calcd for: C18H16FN3O3: C, 63.34; H, 4.72; N,
12.31% found: C, 63.35; H, 4.73; N, 12.30%.
2.5.5. Compound 5e
Brown solid. Yield 80%. mp: 167–169 C. IR (KBr) cm1:
3295, 3164, 1668, 1607, 1172, 1017, 745. 1H NMR
(CDCl3, 300 MHz): 11.20 (s, 1H), 8.54 (d, J= 8.4 Hz,Please cite this article in press as: A. Lavanya et al., Synthesis and biological evalu
Society (2015), http://dx.doi.org/10.1016/j.jscs.2015.06.0081H), 7.44–7.47 (m, 2H), 7.27–7.30 (m, 1H), 6.45 (s, 1H),
5.98 (s, 1H), 3.88 (t, J= 4.8 Hz, 4H), 3.25 (s, 2H), 2.67
(t, J= 4.8 Hz, 4H). 13C NMR (CDCl3, 75 MHz): d
168.30, 162.49, 153.02, 132.24, 127.67, 126.59, 124.34,
122.68, 121.73, 111.28, 66.52, 61.92, 53.48. ESI-MS
(M++1) calculated. m/z 303.1. found 303.9. Anal. Calcd
for: C15H17N3O4: C, 59.40; H, 5.65; N, 13.85% found: C,
59.41; H, 5.66; N, 13.86%.
2.5.6. Compound 5f
Yellow solid. Yield 74%. mp: 127–129 C. IR (KBr) cm1:
3270, 3154, 1668, 1595, 1189, 747. 1H NMR (CDCl3,
300 MHz):d 11.20 (s, 1H), 8.54 (d, J= 8.1 Hz, 1H), 7.43–
7.46 (m, 2H), 7.28 (d, J= 9.3 Hz, 1H), 7.16 (d, J= 5.1 Hz,
1H), 6.91–6.95 (m, 2H), 6.40 (s, 1H), 5.75 (s, 1H), 3.89 (s,
2H), 3.52 (t, J= 6.9 Hz, 2H), 2.32 (t, J= 6.9 Hz, 2H). 13C
NMR (CDCl3, 75 MHz): d 170.51, 162.89, 153.54, 142.02,
132.12, 128.30, 128.17, 127.22, 127.09, 125.42, 123.81, 123.26,
122.14, 111.61, 52.77, 51.35, 30.43. ESI-MS (M++1) calcu-
lated. m/z 343.1. found 344.1. Anal. Calcd for:
C17H17N3O3S: C, 59.46; H, 4.99; N, 12.24% found: C, 59.48;
H, 5.01; N, 12.26%.
2.5.7. Compound 5g
White solid. Yield 82%. mp: 151–153 C. IR (KBr) cm1:
3279, 3178, 1684, 1606, 1181, 737. 1H NMR (CDCl3,
300 MHz): d 11.21 (s, 1H), 8.56 (d, J= 8.4 Hz, 1H), 7.40–
7.45 (m, 2H), 7.28–7.32 (m, 1H), 6.39 (s, 1H), 5.81 (s, 1H),
3.18 (s, 2H), 2.59 (t, J= 4.2 Hz, 4H), 1.71–1.78 (m, 4H),
1.46–1.54 (m, 2H). 13C NMR (CDCl3, 75 MHz): d 169.92,
162.92, 153.53, 132.11, 128.24, 128.16, 127.34, 123.18, 122.21,
111.55, 62.93, 55.22, 26.11, 23.87. ESI-MS (M++1) calcu-
lated. m/z 301.1. found 302.2. Anal. Calcd for: C16H19N3O3:
C, 63.77; H, 6.36; N, 13.94% found: C, 63.78; H, 6.37; N,
13.95%.
2.5.8. Compound 5h
Yellow solid. Yield 69%. mp: 201–203 C. IR (KBr) cm1:
3600, 3268, 3159, 1680, 1600, 1179, 747. 1H NMR
(CDCl3, 300 MHz): d 11.17 (s, 1H), 8.54 (d, J= 8.4 Hz,
1H), 7.40–7.46 (m, 2H), 7.30 (d, J= 8.1 Hz, 1H), 6.44 (s,
1H), 5.78 (s, 1H), 3.60 (d, J= 5.1 Hz, 2H), 3.22 (s, 2H),
2.99–3.01 (m, 2H), 2.27–2.33 (m, 2H), 1.75–1.78 (m, 4H).
13C NMR (CDCl3, 75 MHz): d 171.03, 168.10, 161.18,
151.89, 131.84, 126.52, 125.67, 121.58, 121.05, 110.48,
65.57, 61.28, 53.01, 36.94, 27.84. ESI-MS (M++1) calcu-
lated. m/z 331.1. found 332.2. Anal. Calcd for:
C17H21N3O4: C, 61.62; H, 6.39; N, 12.68% found: C,
61.60; H, 6.37; N, 12.67%.
2.5.9. Compound 5i
White solid. Yield 65%. mp: 125–127 C. IR (KBr) cm1:
3270, 3161, 1681, 1610, 1180, 746. 1H NMR (CDCl3,
300 MHz): d 11.27 (s, 1H), 8.52 (m, 3H), 7.60–7.65 (m, 1H),
7.43–7.49 (m, 2H), 7.25–7.29 (m, 1H), 7.12–7.16 (m, 1H),
6.93 (b, 2H), 3.50 (t, J= 5.1 Hz, 2H), 3.10–3.11 (m, 4H).
13C NMR (CDCl3, 75 MHz): d 174.90, 168.35, 167.43,
157.52, 141.47, 137.42, 134.63, 134.53, 133.57, 133.07, 132.38,
128.31, 115.22, 52.87, 51.38, 30.45. ESI-MS (M++1) calcu-
lated. m/z 338.1. found 339.2. Anal. Calcd for: C18H18N4O3:ation of new benzofuran carboxamide derivatives, Journal of Saudi Chemical
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16.55%.
2.5.10. Compound 5j
Brown solid. Yield 60%. mp: 57–59 C. IR (KBr) cm1: 3271,
3161, 1670, 1597, 1176, 743. 1H NMR (CDCl3, 300 MHz): d
11.29 (s, 1H), 8.52 (d, J= 8.1 Hz, 1H), 8.17 (d, J= 8.4 Hz,
1H), 7.76–7.89 (m, 3H), 7.43–7.54 (m, 5H), 7.26–7.28 (m,
1H), 6.45 (s, 1H), 5.98 (s, 1H), 4.77–4.83 (m, 1H), 3.53 (s,
2H), 1.63 (s, 3H). 13C NMR (CDCl3, 75 MHz) 170.77,
163.11, 153.56, 140.28, 134.05, 132.03, 131.31, 129.09, 128.29,
127.69, 127.32, 126.15, 125.83, 125.58, 123.23, 122.84, 122.09,
111.58, 53.93, 51.29, 23.56. ESI-MS (M++1) calculated. m/z
387.2. found 388.2. Anal. Calcd for: C23H21N3O3: C, 71.30;
H, 5.46; N, 10.85% found: C, 71.29; H, 5.45; N, 10.86%.
2.5.11. Compound 5k
White solid. Yield 73%. mp: 223–225 C. IR (KBr) cm1: 3242,
3198, 1654, 1622, 1186, 768. 1H NMR (DMSO-D6, 300 MHz):
d 11.20 (s, 1H), 8.54 (d, J= 8.4 Hz, 1H), 7.44–7.47 (m, 2H),
7.27–7.30 (m, 1H), 6.45 (s, 1H), 5.98 (s, 1H), 4.75 (t,
J= 6.3 Hz, 4H), 4.67 (t, J= 4.8 Hz, 2H), 3.64 (t,
J= 6.3 Hz, 4H), 3.15 (t, J= 4.8 Hz, 2H), 3.00 (s, 3H). 13C
NMR (DMSO-D6, 75 MHz): d 171.03, 168.10, 161.18,
151.89, 131.84, 126.52, 125.67, 121.58, 121.05, 110.48, 53.01,
51.86, 49.73, 44.58, 36.64. ESI-MS (M++1) calculated. m/z
330.2. found 331.3. Anal. Calcd for: C17H23ClN4O3: C, 55.66;
H, 6.32; N, 15.27% found: C, 55.67; H, 6.33; N, 15.29%.
2.5.12. Compound 5l
Brown solid. Yield 75%. mp: 176–178 C. IR (KBr) cm1:
3266, 3157, 1670, 1599, 1169, 747. 1H NMR (CDCl3,
300 MHz): d 10.74, (s, 1H), 8.33 (d, J= 8.1 Hz, 1H), 7.40–
7.45 (m, 2H), 7.28–7.31 (m, 1H), 6.42 (s, 1H), 5.67 (s, 1H),
3.81 (t, J= 4.8 Hz, 4H), 2.79 (t, J= 6.0 Hz, 2H), 2.66–2.70
(t, J= 6.0 Hz, 2H), 2.59 (t, J= 4.8 Hz, 4H). 13C NMR
(DMSO-D6, 75 MHz): d 169.94, 162.03, 152.69, 132.80,
125.82, 125.53, 124.28, 122.47, 122.36, 111.18, 66.18, 53.80,
52.91, 33.14. ESI-MS (M++1) calculated. m/z 317.1. found
318.1. Anal. Calcd for: C16H19N3O4: C, 60.56; H, 6.03; N,
13.24% found: C, 60.57; H, 6.04; N, 13.25%.
2.5.13. Compound 5m
White solid. Yield 68%. mp: 105–107 C. IR (KBr) cm1:
3287, 3145, 1687, 1617, 1173, 743. 1H NMR (DMSO-D6,
300 MHz): d 10.48 (s, 1H), 8.53 (d, J= 8.1 Hz, 1H), 7.42–
7.46 (m, 2H), 7.29 (d, J= 9.3 Hz, 1H), 7.16 (d, J= 8.1 Hz,
1H), 6.90–6.94 (t, J= 5.1 Hz, 2H), 6.38 (s, 1H), 5.76 (s,
1H),), 3.53 (t, J= 6.9 Hz, 2H), 3.04 (t, J= 6.0 Hz, 2H),
2.70 (t, J= 6.0 Hz, 2H), 2.33 (t, J= 6.9 Hz, 2H). 13C NMR
(DMSO-D6, 75 MHz): d 170.51, 162.89, 153.54, 142.02,
132.12, 128.30, 128.17, 127.22, 127.09, 125.42, 123.81, 123.26,
122.14, 111.61, 53.34, 44.67, 36.58, 33.04. ESI-MS (M++1)
calculated. m/z 357.1. found 358.1. Anal. Calcd for:
C18H20ClN3O3S: C, 54.89; H, 5.12; N, 10.67% found: C,
54.90; H, 5.14; N, 10.68%.
2.5.14. Compound 5n
Yellow solid. Yield 70%. mp: 71–73 C. IR (KBr) cm1: 3272,
3160, 1670, 1610, 1181, 745. 1H NMR (CDCl3, 300 MHz): dPlease cite this article in press as: A. Lavanya et al., Synthesis and biological evalu
Society (2015), http://dx.doi.org/10.1016/j.jscs.2015.06.00810.45 (s, 1H), 8.33 (d, J= 8.1 Hz, 1H), 7.39–7.45 (m, 2H),
7.28–7.30 (m,1H), 7.23 (d, J= 7.8 Hz, 2H), 7.12 (d,
J= 7.8 Hz, 2H), 6.43 (s, 1H), 5.78 (s, 1H), 3.85 (s, 2H), 3.04
(t, J= 6.0 Hz, 2H), 2.69 (t, J= 6.0 Hz, 2H), 2.32 (s, 3H).
13C NMR (DMSO-D6, 75 MHz): d 170.72, 163.01, 153.42,
136.78, 136.70, 132.28, 129.20, 128.27, 128.20, 126.73, 123.19,
122.36, 111.62, 53.44, 44.71, 36.95, 21.14. ESI-MS (M++1)
calculated. m/z 351.2. found 352.3. Anal. Calcd for:
C20H21N3O3: C, 68.36; H, 6.02; N, 11.96% found: C, 68.38;
H, 6.04; N, 11.94%.
2.5.15. Compound 5o
Yellow solid. Yield 78%. mp: 87–89 C. IR (KBr) cm1: 3270,
3161, 1670, 1610, 1180, 746. 1H NMR (CDCl3, 300 MHz): d
10.38 (s, 1H), 8.33 (d, J= 8.1 Hz, 1H), 7.43–7.41 (m, 2H),
7.28–7.34 (m, 3H), 7.00 (t, J= 8.7 Hz, 2H), 6.43 (s, 1H),
5.86 (s, 1H), 3.85 (s, 2H), 3.02–3.06 (t, J= 6.0 Hz, 2H),
2.68–2.72 (t, J= 6.0 Hz, 2H). 13C NMR (CDCl3, 75 MHz):
d 170.64, 163.02, 153.45, 135.61, 132.16, 129.90, 129.80,
128.39, 128.30, 126.75, 123.25, 122.28, 115.41, 115.13, 111.66,
53.04, 44.77, 36.97. ESI-MS (M++1) calculated. m/z 355.1.
found 356.2. Anal. Calcd for: C19H18FN3O3: C, 64.22; H,
5.11; N, 11.82% found: C, 64.00; H, 5.09; N, 11.80%.
2.6. Antimicrobial assay
The synthesized compounds were studied for antimicrobial
activity followed by the reported method [34]. The test organ-
isms were overnight cultured on agar slants, incubated at
37 ± 0.5 C and 24–48 h for bacteria and fungi
(37 ± 0.5 C and 36 h) respectively to get the freshly pre-
pared cultures. The benzofuran derivatives were evaluated
for antimicrobial activity by the well diffusion method.
Muller Hinton Agar (MHA) media was used for bacteria
and Potato dextrose agar (PDA) media was used for fungal
strains respectively. After sterilization the medium was inoc-
ulated with freshly cultured bacterial strains under sterile
condition i.e. under Laminar Flow. The inoculation was
started when the temperature of the medium reached 40–
50 C, so that test organism may not die at higher tempera-
ture. The medium inoculated with test microorganisms was
transferred into the plates of 90 mm size under sterile condi-
tions. The medium was allowed to solidify and the wells (4/-
plate) of 6 mm diameter and 50 lL volume were bored on it
using sterile cork borer. The solution of test compound
1000 lg/mL was prepared in DMSO and the wells bored
on the medium were each ﬁlled (50 lg) with test compound
using micropipette (20–200 lL). Four wells were bored on
the plates and each ﬁlled with same compound and two
plates for each test compound were taken and the experiment
was repeated twice. The discs of amikacin and ketoconazole
were also incorporated into the medium for comparison.
The plates containing test organism and test material in con-
tact were incubated at 37 ± 0.5 C for 24 h. Identical proce-
dure was employed for antifungal activity. However, the
culture strains of fungi and the plates were incubated at
37 ± 0.2 C for 36–72 h. Inhibition of growth of test organ-
isms (bacterial and fungal) in the presence of test material
and standard was measured with the help of standard scale
and the mean values of inhibition zones are shown in
Table 2.ation of new benzofuran carboxamide derivatives, Journal of Saudi Chemical
Table 1 List of synthesized compounds 5a–o.
Entry R Entry R
5a 5i
5b 5j
5c 5k
5d 5l
5e 5m
5f 5n
5g 5o
5h
Biological evaluation of new benzofuran carboxamide derivatives 52.7. Anti-inﬂammatory activity (BSA assay)
The synthesized compounds are screened for anti-inﬂammatory
activity by using inhibition of the albumin denaturation tech-
nique with minor modiﬁcation [35]. The standard drug and syn-
thesized compounds were dissolved in minimum quantity of
Dimethyl formamide (DMF) and diluted with phosphate buffer
(0.2 M, PH 7.4). Final concentration of DMF in all solutions
was less than 2.5%. Test solution (4 mL) containing different
concentrations of drug was mixed with 1 mL of 1 mM albumin
solution in phosphate buffer and incubated at 37 C in incubator
for 15 min. Denaturation was induced by keeping the reaction
mixture at 70 C in water bath for 15 min. After cooling, the tur-
bidity was measured at 660 nm. Percentage of Inhibition of
denaturation was calculated from control where no drug was
added. The diclofenac sodium was used as standard drug. The
percentage inhibition of denaturation was calculated by using
the following formula:
% of Inhibition ¼ 100 ðAtAcÞ=At
At = O.D. of test solution, Ac = O.D. of control.
2.8. Anti-inﬂammatory activity (HRBC assay)
The synthesized compounds were screened for anti-
inﬂammatory activity by using the HRBC method by follow-
ing the procedure reported by Lavanya et al. [35].
2.9. DPPH radical scavenging activity
The DPPH radical scavenging activities of the compounds
were measured by the conventional method [36].
3. Results and discussion
3.1. Chemistry
In the present investigation synthesis of benzofuran derivatives
from 2-hydroxy benzonitrile is shown in Scheme 1 and Table 1.
In the ﬁrst step, the reaction of 2-hydroxybenzonitrile withScheme 1 Synthetic route for benzofuran glyc
Please cite this article in press as: A. Lavanya et al., Synthesis and biological evalu
Society (2015), http://dx.doi.org/10.1016/j.jscs.2015.06.008chloroacetonitrile in the presence of potassium carbonate
afforded the compound 2 with 90% yield [37]. The internal
cyclization of compound 2 in the presence of potassiuminamide and b-alanamide derivatives (5a–o).
ation of new benzofuran carboxamide derivatives, Journal of Saudi Chemical
Figure 3 ORTEP diagram of compound 5g.
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Figure 4 Anti-inﬂammatory activity
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Figure 5 Anti-inﬂammatory activity
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Society (2015), http://dx.doi.org/10.1016/j.jscs.2015.06.008hydroxide in ethanolic medium afforded the key intermediate 3
namely 3-amino benzofuran-2-carboxamide yielded 65%.
Compound 4a was obtained by coupling of chloroacetyl chlo-
ride with compound 3 in 70% yield [38]. The regular nucle-
ophilic substitution of different amines with compound 4a
afforded the corresponding glycinamide based benzofuran
derivatives (5a–j). Similarly compound 4b was obtained by
the coupling of 3-chloropropionyl chloride with compound
3. Further the nucleophilic replacement of different amines
with 4b offered the corresponding b-alanamide based benzofu-
ran derivatives (5k–o). All the synthesized compounds were
characterized by 1H NMR, 13C NMR, IR and Mass spectro-
scopies. The appearance of amide NH peak around 10 ppm
and appearance of broad singlet around 5.5 ppm and
6.0 ppm indicate the presence of amide and carboxamide units
in all these derivatives. The two peaks appeared around
160 ppm in 13C NMR is due to the presence of two carbonylc sodium 
of compound 5a–o (BSA assay).
c sodium 
of compound 5a–o (HRBC Assay).
ation of new benzofuran carboxamide derivatives, Journal of Saudi Chemical
Table 2 Antimicrobial activity of benzofuran derivatives 5a–o (zone of inhibition in mm).
Compound Klebsiella pneumoniae Pseudomonas aeruginosa Staphylococcus aureus Candida albicans Aspergillus Niger
5a 10.2 ± 0.1 – – 12.1 ± 0.2 –
5b 9.9 ± 0.3 12.2 ± 0.1 – 10.1 ± 0.4 –
5c – – – – –
5d – 9.9 ± 0.3 – – –
5e 7.2 ± 0.5 5.3 ± 0.2 – 13.2 ± 0.2 –
5f 11.4 ± 0.1 – – 14.1 ± 0.3 –
5g 10.1 ± 0.5 4.7 ± 0.2 – 15.1 ± 0.1 –
5h 13.2 ± 0.5 7.3 ± 0.4 – 13.8 ± 0.2 –
5i 6.3 ± 0.3 3.2 ± 0.2 11.1 ± 0.1 12.3 ± 0.2 –
5j 14.2 ± 0.3 5.3 ± 0.1 – 12.1 ± 0.1 –
5k 13.0 ± 0.2 10.0 ± 0.2 – 10.2 ± 0.1 –
5l 12.2 ± 0.2 14.0 ± 0.3 – 15.2 ± 0.3 –
5m 9.2 ± 0.1 – 4.1 ± 0.4 12.0 ± 0.3 –
5n 15.9 ± 0.2 – 7.1 ± 0.2 10.0 ± 0.3 –
5o 9.0 ± 0.2 3.1 ± 0.5 21.0 ± 0.3 15.1 ± 0.4 –
Control – – – – -
Ketoconazole – – – 21.0 17.2
Amikacin 17.3 17.1 17.9 – –
Control – Dimethyl sulfoxide.
Standard – ketoconazole for fungi, amikacin for bacteria.
Standard: Ascorbic acid 
Figure 6 DPPH radical scavenging activity of compound 5a–o.
Biological evaluation of new benzofuran carboxamide derivatives 7functional groups. The IR spectrum also conﬁrms the presence
of the carbonyl group. In addition, compound 5o was charac-
terized by 1D DEPT and 2D NMR such as 1H–1H COSY,
13C–1H COSY and HMBC. In DEPT-135 nine carbon signals
appeared, among these 6 positive and 3 negative signals indi-
cate 6 CH units and 3 CH2 units. The correlation of 2.70
and 3.03, 7.00 and 7.30 in 1H–1H COSY and the correlation
of 3.84 and 53.03, 3.03 and 44.76 and 2.70 and 36.97 in
13C–1H COSY indicate the presence of the p-ﬂuorobenzyl
group and ß-alanine group. Similarly the correlation of 3.84
and 44.76, 3.03 and 36.97 and 3.03 and 170.63 in HMBC indi-
cates the ß-alanine unit attached with p-ﬂuorobenzyl unit.Please cite this article in press as: A. Lavanya et al., Synthesis and biological evalu
Society (2015), http://dx.doi.org/10.1016/j.jscs.2015.06.008Compound 5g was conﬁrmed by the X-ray crystallography
method [39] (Fig. 3).
3.2. Biology
3.2.1. Antimicrobial activity
All the synthesized compounds were tested against the
microorganism. In order to determine the antimicrobial activ-
ity, the bacterial strains are chosen as Klebsiella pneumoniae
(ATCC 10031), Pseudomonas aeruginosa (ATCC 10145), and
Staphylococcus aureus (ATCC 11632) and the fungal strains
are Candida albicans (ATCC 66027) and Aspergillus nigeration of new benzofuran carboxamide derivatives, Journal of Saudi Chemical
8 A. Lavanya et al.(ATCC 16404). Amikacin and ketoconazole were used as a
standard for bacterial and fungal strain respectively.
The majority of the compounds were active against K.
Pneumoniae, only the compounds 5c and 5d were inactive.
Similarly most of the compounds were active against
P. aeruginosa except the compounds 5a, 5c, 5m and 5n.
Some of the compounds were active against S. aureus namely
5i, 5m, 5n and 5o. Among these compounds 5o bearing the
p-ﬂuoro benzyl group showed better inhibition than the
standard. Except 5c and 5d, remaining compounds showed
moderate activity against C. albicans. Especially within this
series, the compounds 5g, 5l, and 5m having piperidine, mor-
pholine and thiophene ethylene unit showed better inhibition
against C. albicans. The compounds 5i and 5o bearing pyridyl
ethylene and p-ﬂuoro benzyl unit showed both bacterial and
fungal activities. But all the compounds were unable to inhibit
A. niger. Overall, most of the compounds are active against
K. pneumonia, P. aeruginosa and C. albicans. The zone of inhi-
bition (in mm) of different microorganisms is listed in Table 2.
3.2.2. Anti-inﬂammatory activity (BSA assay)
All the synthesized compounds were studied for their in vitro
anti-inﬂammatory activity by using inhibition of the albumin
denaturation technique with minor modiﬁcation. The activities
of the compounds were checked with four different concentra-
tions (say 50 lm, 100 lm, 300 lm, and 500 lm). Diclofenac
sodiumwas used as a standard. All the compounds showedmod-
erate anti-inﬂammatory activity. Within this series, compounds
5kand 5ohaving theN-methyl piperazine and p-ﬂuorobenzyl unit
showed better activities than 5d, 5f, 5l, 5m and 5n. Compounds 5l,
5m and 5n having the substitution such asmorpholine, thiophene
ethylene and tolyl unit showed lesser activity than other
ß-alanamide derivatives. The different concentrations of
compounds and their inhibitions are represented in Fig. 4.
3.2.3. Anti-inﬂammatory activity (HRBC assay)
The synthesized compounds were studied for their anti-
inﬂammatory activity by using the HRBC method with four
different concentrations of the samples (say 50 lm, 100 lm,
300 lm, and 500 lm) as same as BSA assay. The compounds
showed moderate anti-inﬂammatory activity compared to
standard diclofenac sodium. Within this series, the compounds
5d, 5e, 5k and 5l bearing p-ﬂuoro benzyl, morpholine and N-
methyl piperazine have shown better activity than 5a, 5f, 5h
and 5m and the remaining compounds showed moderate
to good anti-inﬂammatory activity. Anti-inﬂammatory activi-
ties of these derivatives (5a–o) are depending upon the nature
of substitution. Overall the compounds showed better %
inhibitions in HRBC assay compared to BSA assay. The %
inhibitions of synthesized compounds and standard are
represented in Fig. 5.
3.2.4. DPPH radical scavenging activity
The synthesized compounds were studied for radical scaveng-
ing activity against DPPH free radical. All the compounds
showed very good radical scavenging activity. Especially the
compound 5d bearing p-ﬂuoro benzyl unit showed highest rad-
ical scavenging activity among the other compounds. These
derivatives showed rich % inhibitions at high concentrations
such as 100 lm, 150 lm, and 200 lm respectively. There is
not much activity difference between glycinamide derivativesPlease cite this article in press as: A. Lavanya et al., Synthesis and biological evalu
Society (2015), http://dx.doi.org/10.1016/j.jscs.2015.06.008and ß-alanamide derivatives. Because, derivatives of both
series showed almost equal scavenging activities. The %
inhibition of synthesized compounds and standard is repre-
sented in Fig. 6.
4. Conclusion
A series of benzofuran based glycinamides and b-alanamides
were synthesized and their in vitro antimicrobial, anti-
inﬂammatory and radical scavenging activities were studied.
All the synthesized compounds showed moderate activity
against microorganism and radical scavenging activity. The
anti-inﬂammatory activity of 5k and 5o was better than other
compounds. This biological result reveals that these new chem-
ical entities can be a very good starting point for drug discovery
research. The development of modiﬁed benzofuran derivatives
could be a lead molecule. The current research is focused to
synthesize and improves the biological activity of the benzofu-
ran derivatives based on the above results.
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